The RightMed® test for oncology

Aiming to improve the safety and efficacy of medications for oncology patients

Patients with cancer are often taking many medications, including chemotherapy, immune support, infection prophylaxis, plus medications for supportive care. Given the complexities of cancer treatment, finding the right medications for a patient can be difficult and often can cause debilitating side effects for the patient in the process. This is where pharmacogenomics can help.

Pharmacogenomics is the study of how genes affect a person’s response to medications. The OneOme RightMed comprehensive test uses pharmacogenomics to analyze a patient's DNA to determine which medications and dosages may work best, providing valuable information to guide chemotherapy and supportive care decisions.

Download our Guide to the RightMed test for oncology to learn more about how the RightMed comprehensive test may benefit oncology providers and patients.


oncology report

The RightMed oncology report

The RightMed comprehensive test covers hundreds of medications across a broad range of conditions, including medications for oncology, psychiatric conditions, nausea, sleep, pain, and more. With the RightMed test, oncology providers can receive a specialty report that contains a subset of these medications used in oncology, including chemotherapies and supportive care medications.


The RightMed test: Helping oncology patients get the right treatment or dose

Oncology providers have been using somatic genetic testing on tumors for years. Now is the time to supplement that testing with germline pharmacogenomic testing using the OneOme RightMed comprehensive test.

The test results may help identify the right medications or right dose for your patients more quickly, both for chemotherapy and supportive care, potentially resulting in fewer adverse reactions, less trial and error, and more effective treatments for your patients.


cancer icon

HOW THE RIGHTMED TEST MAY HELP WITH PERSONALIZED CHEMOTHERAPY DOSING

The RightMed test covers several chemotherapies commonly used for breast cancer, colorectal cancer, lung cancer, blood cancers, and more. The RightMed test includes both first-line therapies as well as several targeted therapies, also known as the tyrosine kinase receptor inhibitors (TKIs). The RightMed test may help clinicians fine tune the dosing of these medications based on a patient’s genes.

For some chemotherapies, patients who are poor metabolizers (PM) can be at an increased risk for elevated exposure and severe chemotherapy-induced toxicity as a result of the accumulation of toxic compounds. Several first line therapies, such as Capecitabine1, Fluorouracil2, and Irinotecan3 can cause severe side effects such as liver toxicity, myelosuppression, arrhythmia, and death in patients who are poor metabolizers. In these cases the FDA label, CPIC, and other professional guidelines often recommend a simple dose reduction.

The RightMed test includes both pharmacokinetic genes (what the body does to the drug) and pharmacodynamic genes (what the drug does to the body). The genes on the RightMed test that have implications on chemotherapy medication response are pharmacokinetic and include several cytochrome P450 (CYP) genes, UDP glucuronosyltransferase family 1 member 1A (UGT1A1), dihydropyrimidine dehydrogenase (DPYD), nudix hydrolase 15 (NUDT15), and thiopurine S-methyltransferase (TPMT).

CHEMOTHERAPEUTIC AGENTS

MEDICATIONS

Alkylating Agents

Ifosfamide

Antimetabolites

Capecitabine, Fluorouracil, Mercaptopurine, Methotrexate, Thioguanine

Anti-microtubule Agents

Cabazitaxel, Docetaxel, Ixabepilone, Paclitaxel, Vincristine, Vinorelbine

Topoisomerase Inhibitors

Etoposide, Teniposide, Irinotecan

Antiandrogen Agents

Enzalutamide

Anti-estrogen Agent

Exemestane, Tamoxifen

Small Molecule Inhibitors

Axitinib, Bortezomib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Everolimus, Gefitinib, Imatinib, Lapatinib, Nilotinib, Pazopanib, Ponatinib, Regorafenib, Ruxolitinib, Sorafenib, Sunitinib, Vemurafenib

Other

Belinostat, Trabectedin, Temsirolimus


plus icon

HOW THE RIGHTMED TEST MAY HELP WITH SUPPORTIVE CARE

The RightMed test includes many medications often prescribed in an oncology patient’s supportive care, including medications for pain, nausea, vomiting, sleep, hypertension, anxiety, depression, infection prophylaxis, and more.

By using the RightMed comprehensive test when prescribing medications for comorbidities, you may be able to find the right medication faster, reduce the number of adverse drug reactions, and make your patients more comfortable.

Gastrointestinal management (nausea/vomiting, appetite, gastritis, GERD)
Pain management
Neuropathy and non-opioid pain management
Mental health (antidepressants, anxiolytics)
Neuropsychiatry (sleep medicine, anticonvulsant, smoking cessation)
Antimicrobial (antifungal, antibiotic)
Anticoagulant and cardiovascular management

Learn more about the RightMed test by accessing the full medication list.

The benefits of the RightMed test

Pharmacogenomic tests, like the RightMed test, can benefit providers, health systems, and patients. They may help to:

  • adverse icon
    reduce adverse
    drug reactions


  • icon
    improve patient
    adherence

  • icon
    improve
    health and
    economic cost
    effectiveness


  • icon
    optimize dosing

  • icon
    change the
    prescribing
    paradigm from
    reactive
    to preventive

While many patients may benefit from the RightMed comprehensive test, there are specific medical events and conditions which may warrant a pharmacogenomic test for a particular patient more than others. Our Guide to the RightMed test for oncology includes a list of specific use cases.


The RightMed toolkit for providers

Get your copy of OneOme’s Provider toolkit to access more information about the RightMed test, including the medication list and a test requisition form to use in placing your first RightMed test order.


RightMed patient story

“The RightMed test results, for me, mean that I don’t have to be anxious or scared going into a procedure.”
— Pam
Read Pam's full story >

Ready to get started?

mail icon

UPDATES FROM ONEOME

Get the latest from OneOme by signing up for email updates

form icon

TEST REQUISITION FORM

Complete a simple test requisition form to place your first order.

provider icon

PROVIDER TOOLKIT

Get more information, plus the tools you need to get started.

If you are a patient, learn more about the RightMed test and how to get it by downloading our PATIENT TOOLKIT.

This test is not right for everyone. Consult your doctor to see if this test is right for you.



Limitations of the RightMed comprehensive test in oncology
The RightMed test is based on inherited germline gene variations only and does not look at somatic mutations. The RightMed test is a comprehensive test covering many genes and hundreds of medications with clinical evidence supporting the gene-drug interaction. The RightMed test does not cover all chemotherapies.
The use of monoclonal antibodies (e.g., Bevacizumab, Trastuzumab, Cetuximab, etc.) in drug-combination therapy for certain cancers has shown great promise in the clinical setting. While pharmacogenomic testing has been shown to impact patient response to certain monoclonal antibodies, these genes currently are not included on the RightMed comprehensive test. Therefore, the RightMed comprehensive test needs to be accompanied by tumor-specific testing to provide insight on which patients will respond best to monoclonal antibody therapy. The RightMed test is not intended for screening, diagnosing, treating or preventing diseases or medical conditions. This test does not apply to all situations nor does it or should it be interpreted as medical advice.